Taligen Therapeutics taligentherapeutics.com


Public lists: Pharma Startups (4732)

Taligen Therapeutics is a development-stage biotechnology company. In January 2011, Taligen Therapeutics was acquired by Alexion Pharmaceuticals. The valuation of Taligen Therapeutics was $111 million.

Taligen Therapeutics is a development-stage biotechnology company. In January 2011, Taligen Therapeutics was acquired by Alexion Pharmaceuticals. The valuation of Taligen Therapeutics was $111 million.

Company (Acquired)

Phone: 617-299-3200

Fax:

245 First Street
18th Floor Suite 1830
Cambridge, 02142
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Taligen Therapeutics $78.8M Jan 31, 2011
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Taligen Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 7 investors

Competitors

Company Status Description Investors

VLST Corporation

Seattle, Washington, United States
Assets PurchasedVLST (Viral Logic Systems Technology) has developed a streamlined and efficient platform that rapidly yields biological therapeutic compositions of matter with a far greater likelihood of success in clinical trials, particularly in autoimmune and inflammatory disorders. The VLST approach combines bioinformatics and proteomics to provide a rapid and rational approach to identifying new targets for the development of biologic therapies. Moreover, the process used to identify targets also provides ...Show allLogin to see details

Zafgen

Cambridge, Massachusetts, United States
IPO / Went publicZafgen is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity. Beloranib, Zafgen's lead product candidate, is a novel, first-in-class, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in Prader-Willi syndrome, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen was founded in 2005 to explore novel approaches to obesit...Show allLogin to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Humaneered anti-factor b antibody Mar 14, 2008 Jun 21, 2011 Patent